On Aug. 9, the U.S. Food and Drug Administration (FDA) approved Marqibo (vincristine sulfate liposome injection) to treat adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). Read more.
FDA approves Marqibo for rare type of leukemia
Author(s):